Loading
Life sciences · Journal article
Journal of Agricultural and Food Chemistry · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Obesity, a major global health challenge, is closely linked to energy imbalance and gut microbiota disorders, and the key bioactive compounds in ginseng─ginsenosides─have drawn increasing attention for their antiobesity potential. This review outlines the role of the gut microbiota in obesity, describes ginsenosides’ direct antiobesity mechanisms (including appetite suppression, inhibition of fat synthesis, and promotion of energy expenditure), and highlights the bidirectional interaction between ginsenosides and gut microbiota. The gut microbiota metabolizes ginsenosides into more bioactive secondary saponins, which activate key signaling pathways, while conversely, ginsenosides reshape gut microbiota composition by enriching beneficial bacteria and promoting short-chain fatty acid production. This reciprocal interaction improves obesity and related metabolic disorders. Animal studies provide most current evidence, whereas human clinical trials remain limited. Future research should prioritize clinical translation and explore ginsenosides’ combined effects with probiotics.